

IN THE CLAIMS:

Please substitute the following claim set for the set currently of record:

1. (Currently amended) A method to aid in diagnosing glioma, comprising the steps of:
 detecting an expression product of at least one gene in a first brain tissue sample suspected of
 being neoplastic wherein said at least one gene is ~~selected from the group consisting of~~
 signal sequence receptor, delta (translocon-associated protein delta)-DC2 protein;
~~KIAA0404 protein; symplekin; Huntingtin-interacting protein-1; plasmalemma vesicle~~
~~associated protein; KIAA0726 gene product; latexin protein; transforming-growth factor,~~
~~beta 1; hypothetical protein FLJ22215; Rag C protein; hypothetical protein FLJ23471; N-~~
~~myristoyltransferase 1; hypothetical protein dJ1181N3.1; ribosomal protein L27; secreted~~
~~protein, acidic, cysteine-rich (osteonectin); Hs 111988; Hs 112238; laminin, alpha 5;~~
~~protective protein for beta-galactosidase (galactosialidosis); Melanoma-associated gene;~~
~~Melanoma-associated gene; E2 ubiquitin ligase SMURF1; collagen, type IV, alpha 1;~~
~~collagen, type IV, alpha 1; collagen, type IV, alpha 1; insulin-like growth factor binding~~
~~protein 7; gene predicted from cDNA with a complete coding sequence; Thy 1 cell surface~~
~~antigen; Hs 127824; GTP binding protein 2; Homo sapiens mRNA; cDNA DKFZp586D0018~~
~~(from clone DKFZp586D0018); cutaneous T cell lymphoma-associated tumor antigen cc20-~~
~~4; differentially expressed nucleolar TGF-beta1 target protein (DENTT); dysferlin, limb~~
~~girdle-muscular dystrophy 2B (autosomal recessive); smoothelin; integrin, alpha 5~~
~~(fibronectin receptor, alpha polypeptide); putative translation initiation factor; retinoic acid~~
~~induced 14; matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV~~
~~collagenase); Lutheran blood group (Aubergin b antigen included); stannocalcin 2; nuclear~~
~~factor (erythroid derived 2) like 2; protein tyrosine phosphatase, non-receptor type 1;~~
~~integrin, alpha 10; collagen, type VI, alpha 2; chromosome 21 open reading frame 25;~~
~~CDC37 (cell division cycle 37, S. cerevisiae, homolog); Hs 16450; Rho guanine nucleotide~~
~~exchange factor (GEF) 7; creatine kinase, brain; hypothetical protein FLJ10297; hypothetical~~
~~protein FLJ10350; TNF-induced protein; tumor necrosis factor receptor superfamily, member~~
~~12 (translocating chain-association membrane protein); cofilin 1 (non-muscle); splicing~~
~~factor-proline/glutamine-rich (polypyrimidine tract-binding protein-associated); splicing~~
~~factor-proline/glutamine-rich (polypyrimidine tract-binding protein-associated); v-ets avian~~

erythroblastosis virus E26 oncogene homolog 1; protease, cysteine, 1 (legumain); ribosomal protein L13; chromosome 22 open reading frame 5; zinc finger protein 144 (Mel18); degenerative spermatocyte (homolog Drosophila; lipid desaturase); eukaryotic translation initiation factor 2C, 2; mitochondrial ribosomal protein L45; prostate tumor over expressed gene 1; NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (14.5kD, B14.5a); glioma endothelial marker 1 precursor; NS1 binding protein; ribosomal protein L28; tuftelin interacting protein; HLA class II region expressed gene KE2; translocase of inner mitochondrial membrane 17 homolog A (yeast); sudd (suppressor of bimD6, *Aspergillus nidulans*) homolog; heparan sulfate proteoglycan 2 (perlecan); SEC24 (*S. cerevisiae*) related gene family, member A; NADH dehydrogenase (ubiquinone) Fe-S protein 7 (20kD) (NADH coenzyme Q reductase); DNA segment on chromosome X and Y (unique) 155 expressed sequence; annexin A2; Homo sapiens clone 24670 mRNA sequence; hypothetical protein; matrix metalloproteinase 10 (stromelysin 2); KIAA1049 protein; G protein coupled receptor; hypothetical protein FLJ20401; matrix metalloproteinase 14 (membrane inserted); KIAA0470 gene product; solute carrier family 20 (nucleoside transporters), member 1; stannocalcin 1; stannocalcin 1; stannocalcin 1; tumor suppressor deleted in oral cancer related 1; tumor suppressor deleted in oral cancer related 1; apolipoprotein C-1; glutathione peroxidase 4 (phospholipid hydroperoxidase); Hs 272106; transcription factor binding to IGHM enhancer 3; hypothetical protein DKFZp762A227; hypothetical protein FLJ22362; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EJ32 and G344); PRO0628 protein; melanoma associated antigen recognised by cytotoxic T lymphocytes; LOC88745; Homo sapiens beta 1,2 galactosyltransferase 6 (B3GALT6) mRNA, complete cds; sprouty (Drosophila) homolog 4; sprouty (Drosophila) homolog 4; Homo sapiens mRNA; cDNA DKFZp434E1515 (from clone DKFZp434E1515); coactosin-like protein; hypothetical protein FLJ21865; Hs296234; KIAA0685 gene product; hypothetical protein FLJ10980; ribosomal protein L10; ribosomal protein S19; Hs 299251; Huntingtin interacting protein K; Homo sapiens mRNA full length insert cDNA clone EUROMAGE 50374; Hs 311780; Hs 212191; v-akt murine thymoma viral oncogene homolog 2; Hs 328774; transducin-like enhancer of split 2, homolog of Drosophila E(sp1); KIAA1870 protein; ribosomal protein L10a; peptidylprolyl isomerase A (cyclophilin A); Hs 344224; hypothetical protein FLJ22239; hypothetical protein DKFZp761H221; KIAA1887

protein; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 704679; Homo sapiens cDNA FLJ30634 fis, clone CTONG2002453; Homo sapiens cDNA FLJ32203 fis, clone PLACE6003038, weakly similar to ZINC FINGER PROTEIN 84; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1035004; hypothetical protein LOC57333; myosin ID; plexin B2; lectin, galactoside-binding, soluble, 8 (galactin 8); double ring finger protein, Dofrin; DKFZP424B168 protein; LIM domain binding 2; integrin beta 4 binding protein; synaptopodin; Hs 54828; insulin induced gene 1; acetyl LDL receptor; SREC; excision repair cross-complementing rodent repair deficiency; complementation group 1 (includes overlapping antisense sequence); hypothetical protein FLJ22329; schwannomin interacting protein 1; PTEN induced putative kinase 1; myosin X; Homo sapiens cDNA FLJ32424 fis, clone SKMUS2000954, moderately similar to Homo sapiens F-box protein Fbx25 (FBX25) 97; golgi phosphoprotein 1; splicing factor, arginine/serine-rich 6; laminin, gamma 3; cysteine-rich protein 2; U6 snRNA associated Sm-like protein LSM7; hypothetical protein FLJ10707; Homo sapiens, Similar to RIKEN cDNA 2310012N15 gene; clone IMAGE3342825, mRNA, partial cds; macrophage migration inhibitory factor (glycosylation-inhibiting factor); ubiquinol cytochrome c reductase hinge protein; gap junction protein, alpha 1, 43kD (connexin 43); dihydropyrimidinase like 3; aquaporin 1 (channel forming integral protein, 28kD); protein expressed in thyroid; macrophage myristoylated alanine-rich C kinase substrate; procollagen lysine, 2-oxoglutarate 5-dioxygenase (lysine-hydroxylase, Ehlers-Danlos syndrome type VI); protease, serine, 11 (IGF-binding); 24-dehydrocholesterol reductase; collagen, type IV, alpha 2; profilin 1; apolipoprotein D; hyaluronoglucosaminidase 2; hypothetical protein FLJ22678; quiescin Q6; ras homolog gene family, member A; ras homolog gene family, member A; plasminogen activator, urokinase; insulin-like growth factor binding protein 3; uridine phosphorylase; KIAA0638 protein; B7 homolog 3; lamin A/C; lamin A/C; lamin A/C; regulator of G-protein signalling 12; proteasome (prosome, macropain) 26S subunit, non-ATPase, 8; Homo sapiens, Similar to RIKEN cDNA 5730528L13 gene, clone MGC17337 IMAGE4213591, mRNA, complete cds; prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy); laminin, alpha 4; transcription elongation factor A (SII), 1; lectin, galactoside-binding, soluble, 3-binding protein; ribosomal protein S16; glycophorin C (Gerbich blood group); endothelin receptor type B; serine (or cysteine) proteinase inhibitor;

elade E (nexin, plasminogen activator-inhibitor type 1), member 1; biglycan; small nuclear ribonucleoprotein polypeptide B"; transmembrane 4 superfamily member 2; TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28 kD; lysyl oxidase-like 2; SRY (sex determining region Y) box 4; SOX4 SRY (sex determining region Y) box 4; SRY (sex determining region Y) box 4; actin related protein 2/3 complex, subunit 2 (34 kD); Homo sapiens cDNA: FLJ22507 fis, clone LNG03128; hypothetical protein FLJ12442; Fas (TNFRSF6) associated via death domain; mitogen-activated protein kinase kinase kinase 11; TEK-tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal); insulin receptor; cell membrane glycoprotein, 110000M(r) (surface antigen); Homo sapiens cDNA FLJ11863 fis, clone HEMBA1006926; jagged 1 (Alagille syndrome); KIAA0304 gene product; pre-B-cell leukemia transcription factor 2; Homo sapiens cDNA FLJ31238 fis, clone KIDNE2004864; p53-induced protein; complement component 1, q subcomponent; receptor 1; complement component 1, q subcomponent; receptor 1; apolipoprotein E; chemokine (C-C motif) ligand 3; coagulation factor II (thrombin) receptor-like 3; coagulation factor III (thromboplastin, tissue factor); collagen, type I, alpha 1; collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant); C type (calcium dependent, carbohydrate recognition domain) lectin, superfamily member 9; cystatin C (amyloid angiopathy and cerebral hemorrhage); endoplasmic reticulum associated protein 140 kDa; ESTs; ESTs; ESTs; Highly similar to hypothetical protein FLJ10250 [Homo sapiens] [H.sapiens]; ESTs; Highly similar to ITBI_HUMAN Integrin beta 1 precursor (Fibronectin receptor beta subunit) (CD29) (Integrin VLA-4 beta subunit) [H.sapiens]; ESTs; Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]; ESTs; Weakly similar to T17346 hypothetical protein DKFZp586O1624.1 human (fragment) [H.sapiens]; ESTs; Weakly similar to T21371 hypothetical protein F25H8.3 Caenorhabditis elegans [C.elegans]; eukaryotic translation initiation factor 4A, isoform 1; heme oxygenase (deacyling) 1; Hermansky-Pudlak syndrome 4; Homo sapiens cDNA FLJ34888 fis, clone NT2NE2017232; Homo sapiens cDNA FLJ39848 fis, clone SPLEN2014669; Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059; Homo sapiens, clone IMAGE:4845226, mRNA; hypothetical protein FLJ22329; hypothetical protein FLJ32205; hypothetical protein MGC4677; inhibin, beta B (activin AB beta polypeptide); insulin-like growth factor binding protein 5; junction plakoglobin; KIAA0620 protein; KIAA0043

~~protein; likely ortholog of rat vacuole membrane protein 1; Lysosomal-associated
multispanning membrane protein 5; major histocompatibility complex, class I, B; major
histocompatibility complex, class I, C; matrix Gla protein; matrix metalloproteinase 1
(interstitial collagenase); microtubule-associated protein 1 light chain 3 beta; nerve growth
factor receptor (TNFR superfamily, member 16); ribosomal protein S9; ring finger protein
40; S100 calcium-binding protein, beta (neural); sema domain, transmembrane domain (TM),
and cytoplasmic domain, (semaphorin) 6B; SPARC-like 1 (mast9, hevin); tumor necrosis
factor, alpha-induced protein 3; UDP-Gal:betaGlcNAc-beta 1,4-galactosyltransferase;
polypeptide-3; UDP-GlcNAc:betaGal-beta 1,3-N-acetylglucosaminyltransferase-5; von
Willebrand factor; v-akt murine thymoma viral oncogene homolog 2; cyclin-dependent kinase
(cdk2-like) 10; ortholog mouse myocyte induction/differentiation originator; brain-specific
angiogenesis inhibitor 1; EGF-TM7 latrophilin-related protein; sema domain; integrin,
alpha-5; likely ortholog of mouse fibronectin type III; Lutheran blood group (Auburger b
antigen included); SSR4, TRAPD; nerve growth factor receptor (TNFR superfamily, member
16); insulin-like growth factor-binding protein; leukemia-inhibitory factor; protein tyrosine
phosphatase, nonreceptor type I; and Homo sapiens, clone IMAGE:3908182, mRNA, partial
eds;~~

and

comparing expression of the at least one gene in the first brain tissue sample with
expression of the at least one gene in a second brain tissue sample which is normal,
wherein increased expression of the at least one gene in the first brain tissue sample
relative to the second tissue sample identifies the first brain tissue sample as likely to be
neoplastic.

2. (Original) The method of item 1 wherein the increased expression of the at least one
gene in the first brain tissue sample relative to the second tissue sample is at least two-
fold higher.
3. (Original) The method of item 1 wherein the increased expression of the at least one
gene in the first brain tissue sample relative to the second tissue sample is at least five-
fold higher.

4. (Original) The method of item 1 wherein the increased expression of the at least one gene in the first brain tissue sample relative to the second tissue sample is at least ten-fold higher.
5. (Original) The method of item 1 wherein the expression product is RNA.
6. (Original) The method of item 1 wherein the expression product is protein.
7. (Original) The method of item 1 wherein the first and second tissue samples are from a human.
8. (Original) The method of item 1 wherein the first and second tissue samples are from the same human.
9. (Original) The method of item 1 wherein the step of detecting is performed using a Western blot.
10. (Original) The method of item 1 wherein the step of detecting is performed using an immunoassay.
11. (Original) The method of item 1 wherein the step of detecting is performed using an immunohistochemical assay.
12. (Original) The method of item 1 wherein the step of detecting is performed using SAGE.
13. (Original) The method of item 1 wherein the step of detecting is performed using hybridization to a microarray.
- 14-67. (Cancelled)